JONATHAN BEHR

Profile

First Name

: JONATHAN

Middle Name

:

Last Name

: BEHR

Related Companies

Titles

Company Name

Related People

DIRECTOR

IMMUNOMOLECULAR THERAPEUTICS, INC.

JASON DINGES, SEAN DOHERTY, PETER GOTTLIEB, AARON MICHELS, STEVE ORNDORFF, ED ORR, NANDAN PADUKONE, TOM SHEA

DIRECTOR

VERALOX THERAPEUTICS INC.

MATTHEW BOXER, KATIE ELLIAS, CHRISTOPHER GAGLIARDI, MEGAN KRENCH, DAVID MALONEY, ALEX MARTIN, JONATHAN MOW, BENJAMIN SCRUGGS, JAMIE STIFF, JEFFREY W. STROVEL

DIRECTOR

NITROME BIOSCIENCES, INC

MARGARITA CHAVEZ, IRENE GRISWOLD-PRENNER, ZACH HALL, ZACH W. HALL, EPHRAIM HELLER, EPHREIM HELLER, REGIS KELLY, WILLIAM MCDOWELL, HENRIJETTE RICHTER

DIRECTOR

JASON BROWN, ROEL BULTHUIS, HAGEN CRAMER, LAIA CRESPO-MARTIN, LUC DOCHEZ, DANIEL ELBAUM, JONATHAN FLEMING, JOHANNES FRUEHAUF, ANGELA GENGE, MICHAEL HUTTON, CILLIAN KING, KASPER C.D. ROET, AMY SCHULMAN, VIKAS SHARMA, CHRIS THOMAJAN, JULIO E. VEGA, SHAFIQUE VIRANI, ANNE WHITAKER

DIRECTOR

ENDLYZ THERAPEUTICS, INC.

LAURENCE BARKER, DAMIAN CROWTHER, TIMOTHY EDWARDS, JUSTIAN CRAIG FOX, JOHN GUSTOFSON, ZAVEN KAPRIELIAN, DONMIENNE LEUNG, JOANNA WOLAK

EXECUTIVE OFFICER

DEMENTIA DISCOVERY FUND 2 LP

HOUMAN ASHRAFIAN, LAURENCE BARKER, KATE BINGHAM, JAMES COSTINE, N/A DDF 2 GP LLP, CHRISTIAN JUNG, N/A SV HEALTH MANAGERS LLP

DIRECTOR

VIOLET THERAPEUTICS, INC.

MEREDITH FISHER, ATSUSHI USAMI, WILLIAM E YELLE

Filings

Filing Date

Filing Type

Source URL

Industry Classifier

Detailed Industry

Revenue Range

Securities

First Sale Date

D/A

VENTURE CAPITAL FUND

DECLINE TO DISCLOSE

Equity

2022-03-10

D

OTHER

DECLINE TO DISCLOSE

Equity

2023-04-20

D/A

VENTURE CAPITAL FUND

DECLINE TO DISCLOSE

Equity

2022-03-10

D

PHARMACEUTICALS

DECLINE TO DISCLOSE

Debt

2022-08-12

D

VENTURE CAPITAL FUND

DECLINE TO DISCLOSE

Equity

2022-03-10

D

BIOTECHNOLOGY

DECLINE TO DISCLOSE

Equity

2021-07-16

D

PHARMACEUTICALS

DECLINE TO DISCLOSE

Equity

2020-05-01

D

BIOTECHNOLOGY

DECLINE TO DISCLOSE

Equity

2020-04-08

D

BIOTECHNOLOGY

DECLINE TO DISCLOSE

Equity

2019-06-04

D

BIOTECHNOLOGY

DECLINE TO DISCLOSE

Debt

2019-05-10